XRCC3 and melanoma: The results for the XRCC3 Thr241Met variant have so far been not been conclusive: variant carriers was found to have increased risk of bladder and breast cancer and malignant melanoma [30-32], whereas in a previous study of ours no association with this marker and bladder cancer was demonstrated [8].